EUCTR2006-000207-42-IT进行中（未招募）不适用
A 24-weeks , national, multicenter, double blind controlled vs placebo trial to evaluate the efficacy of Neoral ciclosporine 5mg/kg/day , twice a week administered in reduction of the rate of relapse in pz with chronic plaque psoriasis on remission. PREWENT Study - PREWENT Study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •XXXX18 Age 65 years; Patients with chronic plaque psoriasis on remission PASI 8804;75 of PASI before Neoral treatment course after a treatment course with Neoral given continuously for 8 but 16 weeks;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients on remission after a treatment course with other drugs than Neoral Body weight 110 kg; Patients with abnormal renal function creatinine 10 UNL Patients with severe chronic degenerative diseases Severe uncontrolled hypertension Severe uncontrolled hyperlipidemia Bilirubin or liver enzymes 2 the UNL; Platelets count 75,000 mm3 with neutrophils 1,500 mm3 and/or leucopenia 2,500 mm3 , or anaemia emoglobine 6g/dl at basal Clinically significant uncontrolled bacterial, viral or fungal infection
研究者
相似试验
招募中
不适用
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin TherapyEndocrine, nutritional and metabolic diseaseKCT0000937MSD Korea800
进行中（未招募）
1 期
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients with High Bad Cholesterol or Low Good Cholesterol (HDL-C)Hypercholesterolemia or Low HDL-CEUCTR2012-003110-14-NLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.459
进行中（未招募）
不适用
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients with High Bad Cholesterol or Low Good Cholesterol (HDL-C)EUCTR2012-003110-14-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.450
进行中（未招募）
不适用
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients with High Bad Cholesterol or Low Good Cholesterol (HDL-C)EUCTR2012-003110-14-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.450
进行中（未招募）
1 期
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients with High Bad Cholesterol or Low Good Cholesterol (HDL-C)Hypercholesterolemia or Low HDL-CEUCTR2012-003110-14-ROMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.459